Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy #  00829
Original Effective Date:  04/01/2023
Current Effective Date:  04/01/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Medical Management of Obstructive Sleep Apnea Syndrome is addressed separately in medical policy 00328.

Chronic Obstructive Pulmonary Disease (COPD)

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider nocturnal bilevel positive airway pressure (BiPAP) with backup rate for patients with chronic obstructive pulmonary disease (COPD) and chronic respiratory failure (see Policy Guidelines) to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility will be met for nocturnal BiPAP with backup rate for patients with COPD and chronic respiratory failure who meet EITHER of the following:

• Chronic stable daytime (awake) hypercapnia (PaCO$_2$ ≥ 52 mmHg); OR
• Daytime (awake) hypercapnia (PaCO$_2$ ≥ 52 mmHg) at least 2 weeks after discharge from the hospital for an acute exacerbation with decompensated acidosis.

Based on review of available data, the Company may consider non-invasive home mechanical ventilation (HMV) for patients with chronic obstructive pulmonary disease (COPD) and chronic respiratory failure to be eligible for coverage.**
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy #  00829
Original Effective Date:  04/01/2023
Current Effective Date:  04/01/2023

Patient Selection Criteria
Coverage eligibility will be met for non-invasive HMV for patients with COPD and chronic respiratory failure who meet the following:

- Persistence of hypercapnia with PaCO$_2$ > 52 mmHg despite 3 months of adequate adherence to BiPAP therapy (see Policy Guidelines); OR
- Qualify for a BiPAP device AND meet AT LEAST ONE of the following:
  - Higher pressure (e.g., > 25 cm H2O) is needed to reduce hypercapnia than can be achieved with a BiPAP device during titration; OR
  - Severe hypoxemia requiring FIO$_2$ > 40% or > 5 L/min nasally; OR
  - Daytime use (battery operated unit) is required to reduce hypercapnia.

Note:
Individuals who are started on BiPAP at discharge from hospitalization for acute hypercapnic respiratory failure (PaCO$_2$ > 52 mmHg) may continue BiPAP for up to 3 months to provide time to stabilize and complete reevaluation.

Request for initial non-invasive HMV can be approved for 3 months and continuation requests will be reviewed every 6 months.

Individuals who failed BiPAP during hospitalization for acute hypercapnic respiratory failure (persistent PaCO$_2$ > 52 mmHg) and required non-invasive mechanical ventilation at time of discharge from hospital may be considered for non-invasive HMV for up to 3 months to provide time to stabilize and complete reevaluation. Continued use of non-invasive HMV beyond initial 3 months may be considered if patient used non-invasive HMV device on average 4 hours per 24-hour period and continues to have hypercapnia with PaCO$_2$ > 52 mmHg, requires higher pressure (e.g., > 25 cm H2O), FIO$_2$ > 40% or requires daytime HMV to reduce hypercapnia.

Patient Selection Criteria for Continuation of non-invasive HMV for COPD after initial 3-month use (and for subsequent recertifications every 6 months)

Continuation of non-invasive HMV for COPD, when the following criteria are met, may be considered eligible for coverage**

- Patient has documented improvement of relevant signs and symptoms due to device use AND
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

- Patient used non-invasive HMV device on average 4 hours per 24-hour period (see Policy Guidelines).

**Thoracic Restrictive Disorders (Neuromuscular Diseases)**

Based on review of available data, the Company may consider nocturnal bilevel positive airway pressure (BiPAP) for patients with thoracic restrictive disorders (TRD) to be eligible for coverage.

Patient Selection Criteria
Coverage eligibility will be met for nocturnal BiPAP for patients with TRD (see Policy Guidelines) who meet ANY of the following:
- Spirometry (upright or supine) with Vital Capacity (VC) < 50% predicted or < 80% predicted with associated symptoms (i.e., orthopnea, dyspnea, morning headaches, excessive daytime sleepiness, or nonrefreshing sleep); OR
- Force testing (upright or supine) with Maximal Inspiratory Pressure (MIP) < 60 cm H2O; OR
- Hypercapnia
  - Chronic stable daytime (awake) hypercapnia with PaCO2 ≥ 45 mmHg (ABG); OR
  - Venous blood gas PCO2 (VBG PCO2), end-tidal PCO2 (EtPCO2) or transcutaneous PCO2 (TcPCO2) ≥ 50 mmHg; OR
- Hypoxia
  - Overnight oximetry in-laboratory or home sleep test with saturation < 88% for 5 minutes or longer.

Based on review of available data, the Company may consider non-invasive home mechanical ventilation (HMV) for patients with thoracic restrictive disorders (TRD) to be eligible for coverage.

Patient Selection Criteria
Coverage eligibility will be met for non-invasive HMV for patients with TRD who meet the following:
- Qualify for a BiPAP device and extreme loss in function with vital capacity (VC) < 30%.
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy #  00829
Original Effective Date:  04/01/2023
Current Effective Date:  04/01/2023

OR

• Finding needed to advance to HMV following nocturnal use of BiPAP when ANY of the following are met:
  o Non-invasive ventilation is needed for > 10 hours per day; OR
  o Severe breathlessness (i.e., with speaking at rest); OR
  o Worsening daytime hypercapnia with need for mouthpiece ventilation; OR
  o Daytime use (battery operated unit) is required to reduce hypercapnia or dyspnea.

Note:
Request for initial non-invasive HMV can be approved for 3 months and continuation requests will be reviewed every 6 months.

Patient Selection Criteria for Continuation of non-invasive HMV for TRD after initial 3-month use (and for subsequent recertifications every 6 months)

Continuation of non-invasive HMV for TRD, when the following criteria are met, may be considered eligible for coverage**

• Patient has documented improvement of relevant signs and symptoms due to device use AND

• Patient used non-invasive HMV device on average 4 hours per 24-hour period (see Policy Guidelines).

Hypoventilation Syndrome

Based on review of available data, the Company may consider bilevel positive airway pressure (BiPAP) for patients with hypoventilation syndrome to be eligible for coverage,**

Patient Selection Criteria

Coverage eligibility will be met for BiPAP for patients with hypoventilation syndrome (see Policy Guidelines) who meet ALL of the following:

• Awake or sleep hypoventilation with hypercapnia (one of the following is met):
  o Awake hypoventilation with chronic stable daytime (awake) hypercapnia:
    ▪ PaCO₂ > 45 mmHg (ABG); or

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 4 of 24
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

- Venous blood gas PCO2 (VBG PCO2), end-tidal PCO2 (EtPCO2) or transcutaneous PCO2 (TcPCO2) ≥ 50 mmHg; or
  - Sleep hypoventilation with hypercapnia:
    - ≥ 10 mmHg increase from baseline awake PCO2 and to a value > 50 mmHg for ≥ 10 min; or
    - PCO2 ≥ 55 mmHg for ≥ 10 min; **AND**
- Low clinical suspicion for COPD or neuromuscular disease; **AND**
- One of the following conditions are met:
  - Obesity with BMI ≥ 30 kg/m²; or
  - Decreased respiratory drive due to opioid or substance use; or
  - Advanced lung disease other than COPD (e.g., end-stage or advanced interstitial lung disease); **AND**
- Individual was discharged from inpatient stay with persistent awake hypoventilation (hypercapnia) on BiPAP
  - A reassessment with a provider within 3 months (30-90 days) is required and an attended polysomnogram (PSG) should be performed to assess appropriateness of PAP modality (home sleep apnea test is acceptable if attended PSG is not obtainable); **OR**
- Individual is ambulatory and sleep study indicates that BiPAP is necessary for sleep-disordered breathing, or patient with severe OSA is CPAP/APAP intolerant or CPAP/APAP was proven ineffective.

Based on review of available data, the Company may consider non-invasive home mechanical ventilation (HMV) for patients with hypoventilation syndrome to be **eligible for coverage.**

**Patient Selection Criteria**
Coverage eligibility will be met for non-invasive HMV for patients with hypoventilation syndrome who meet the following:
- Qualify for a BiPAP **AND** meet **AT LEAST ONE** of the following:
  - Higher pressure (e.g., > 25 cm H2O) is needed to reduce hypercapnia than can be achieved with a BiPAP device during titration; or
  - Severe hypoxemia requiring FIO2 > 40% or > 5 L/min; or
  - Daytime use (battery operated unit) is required to reduce hypercapnia; **OR**
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829  
Original Effective Date: 04/01/2023  
Current Effective Date: 04/01/2023

- Tried and failed BiPAP device with persistent hypercapnia despite 3 months of adequate adherence (see Policy Guidelines) to prescribed PAP therapy with:
  - Awake PaCO₂ ≥ 45 mmHg (ABG); or
  - Awake venous blood gas PCO₂ (VBG PCO₂), end-tidal PCO₂ (EtPCO₂) or transcutaneous PCO₂ (TcPCO₂) ≥ 50 mmHg.

Note:
Request for initial non-invasive HMV can be approved for 3 months and continuation requests will be reviewed every 6 months.

Patient Selection Criteria for Continuation of non-invasive HMV for hypoventilation syndrome after initial 3-month use (and for subsequent recertifications every 6 months)

Continuation of non-invasive HMV for hypoventilation syndrome, when the following criteria are met, may be considered eligible for coverage**

- Patient has documented improvement of relevant signs and symptoms due to device use AND
- Patient used non-invasive HMV device on average 4 hours per 24-hour period (see Policy Guidelines).

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers Continuation of Non-Invasive Positive Airway Pressure when continuation criteria are not met to be not medically necessary.**

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers non-invasive positive airway pressure under all other conditions to be investigational.*

The use of non-invasive positive airway pressure when patient selection criteria are not met is considered to be investigational.*
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy #  00829
Original Effective Date:  04/01/2023
Current Effective Date:  04/01/2023

**Policy Guidelines**

**COPD**

Respiratory failure in patients with COPD is characterized by the inability to sustain normal gas exchange, leading to low arterial blood oxygen (hypoxemia, PaO$_2$) and/or high arterial carbon dioxide (hypercapnia, PaCO$_2$). Assessment of hypoxemia would lead to supplemental oxygen administration. Stable clinical state is defined as free of exacerbations for at least 4 weeks with pH over 7.35.

Compliance with treatment of at least 4 hours per 24 hours should be documented after the first 3 months of use. There are limited data on which to base compliance assessment. Assessment could be further based on an *average* of at least 4 hours per 24 hours over a consecutive 30-day period or use of 4 hours per 24 hours for at least 65% of the days in a consecutive 30-day period.

The Centers for Medicare and Medicaid Services (CMS) classifies a respiratory assist device as a bilevel positive airway pressure device with or without backup respiratory rate capability. Treatment modalities that are reported with the E0471 code include BiPAP ST, ASV, BiPAP AutoSV, iVAPS, AVAPS. BiPAP units with batteries have a battery life that is shorter than home mechanical ventilators and are infrequently used in the U.S.

CMS defines non-invasive mechanical ventilators as life supporting/sustaining devices used in various settings, including home, hospital, and institutional settings. The non-invasive mechanical ventilators should have at least 6 pressure modes and 3 volume modes, and allow for both invasive or non-invasive use. For examples, see the Regulatory Status section.

Although most patients with comorbid COPD and obstructive sleep apnea can be effectively treated with continuous or auto-adjusting positive airway pressure, approximately 10% of patients will need bilevel positive airway pressure to tolerate the required pressure. These devices are reviewed in medical policy 00328 (Medical Management of Obstructive Sleep Apnea Syndrome).

Respiratory therapy in the home may be provided for patients with COPD who are treated with E0466, E0470, or E0471 devices.
Thoracic Restrictive Disorders (Neuromuscular Disease)

Thoracic restrictive disorders (TRDs) are characterized by restrictive respiratory physiology due to weakness from neuromuscular diseases (NMDs) and/or chest wall deformity. TRDs often lead to disturbed sleep architecture, sleep hypoventilation, and ultimately daytime hypoventilation. The leading causes of death and major morbidity in these diseases are respiratory infection and respiratory failure.

Diagnostic groups contained in TRD category include spinal cord injury, muscular dystrophy, motor neuron diseases (e.g., ALS), ion channel diseases, myopathies, mitochondrial diseases, neuromuscular junction diseases (e.g., myasthenia gravis), phrenic nerve diseases (diaphragmatic paralysis), impaired respiratory drive disorders, e.g., Chiari malformation or central congenital hypoventilation, and thoracic cage abnormalities (e.g., severe scoliosis).

Hypoventilation Syndrome

Hypoventilation syndromes are a heterogeneous group of disorders caused by loss of normal homeostasis and are characterized by hypercapnia, defined as a $\text{PaCO}_2 > 45$ mmHg at sea level. Noninvasive ventilation (NIV) includes a group of bilevel positive airway pressure (BiPAP) devices that are effective in improving hypercapnia and are accepted as standard of care for treating various hypoventilation syndromes. Obesity is a leading cause of hypoventilation in the United States, and obesity hypoventilation syndrome (OHS) refers to the development of awake daytime hypercapnia in obese individuals ($\text{BMI} \geq 30$ kg/m2) in the absence of other known causes of hypoventilation. OHS is associated with significant morbidity and higher risk of hospitalizations, ICU utilization, and death.

Background/Overview

Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a common condition, affecting more than 5% of the population, and is associated with high morbidity and mortality. COPD is the fourth leading cause of death in the United States. It is a clinical syndrome with multiple etiologies that is characterized by chronic respiratory symptoms, structural pulmonary abnormalities, and/or lung function impairment. Chronic obstructive pulmonary disease is most frequently associated with cigarette smoking or other air pollutants, and a majority of patients with COPD in the United States have a history of cigarette smoking. Chronic obstructive pulmonary disease is progressive, with
expiratory airflow limitation, air trapping/hyperinflation, and destruction of alveoli (emphysema). The Global Initiative for Chronic Obstructive Lung Disease (GOLD), defines COPD as "a common, preventable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases and influenced by host factors including abnormal lung development”.

Respiratory failure in patients with COPD is characterized by the inability to sustain normal gas exchange, leading to low arterial blood oxygen (hypoxemia, PaO$_2$) and/or high arterial carbon dioxide (hypercapnia, PaCO$_2$). Hypercapnia develops in about one-third of patients with COPD and is associated with poor quality of life, sleepiness, frequent hospital admissions due to exacerbations, and an increase in mortality compared to patients with COPD who are normocapnic. The hypercapnia is due in large part to poor lung biomechanics including low inspiratory muscle reserve, high CO$_2$ production, and a reduced ventilatory capability. The imbalance between the respiratory load and respiratory capability may in turn affect the ventilatory control center in the brain stem. Physiological changes in responsiveness to hypoxemia and hypercapnia during sleep can be particularly pronounced in patients with COPD, with overnight increases in PaCO$_2$ affecting daytime PaCO$_2$, possibly through bicarbonate retention or changes in cerebrospinal fluid. Patients with COPD may also have comorbid obstructive sleep apnea and/or obesity hypoventilation syndrome due to decreased ventilatory motor output and upper airway muscle activity during sleep.

**Treatment With Non-invasive Positive Airway Pressure**

Initial treatment is pharmacological with inhaled (eg, bronchodilators and glucocorticoids) and oral medications. Long-term oxygen may also be used for patients who have severe hypoxemia.

A major goal of management of patients with COPD is to reduce hospitalizations and mortality. Long-term oxygen therapy is recommended for patients with poor clinical status and noninvasive positive airway pressure ventilation (NPPV) devices for patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure. Noninvasive positive airway pressure ventilation devices include nocturnal continuous positive airway pressure (CPAP) for individuals with hypercapnia due to obstructive sleep apnea or hypoventilation and bilevel positive airway pressure (BiPAP) devices or non-invasive home mechanical ventilators that are pressure, rate, and volume targeted. The objective of this medical policy is to describe which features of NPPV are required to improve the net health outcome in patients with COPD.
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy #  00829  
Original Effective Date:  04/01/2023  
Current Effective Date:  04/01/2023

Benefits of nocturnal NPPV persist into the daytime with improved breathing patterns (lower frequencies and larger tidal volumes) and improved gas exchange. Explanations for the improvement in daytime respiration with nocturnal NPPV include increased respiratory drive, improved diaphragm function by unloading the respiratory muscles during sleep, increased CO₂ sensitivity, and reduction in air trapping and hyperinflation. It is not known which factors (eg, muscle unloading, gas exchange normalization, decrease in hyperinflation) underlie the benefits of NPPV on health outcomes. It is also unclear if the reduction in PaCO₂ has an effect on health outcomes or if it is only a marker of effective ventilation.

Respiratory Assist Devices
The Centers for Medicare and Medicaid Services (CMS) defines respiratory assist devices (RADs) as bilevel devices with or without back-up respiratory rate capability. While CPAP devices provide continuous air at a pressure that prevents the collapse of the airway during inspiration, BiPAP devices work by increasing pressure during inspiration and lowering it during expiration (pressure cycled). In some devices a backup respiratory rate is triggered when the patient's nocturnal respiratory rate decreases below a set threshold. The backup rate is typically set 2 breaths below the patient's spontaneous respiratory rate during wakefulness.

Terminology on device features is described in Table 1.

Table 1. Device Features

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilevel-S</td>
<td>Bilevel without a backup rate</td>
<td>Positive airway pressure that is higher during inspiration than expiration that is triggered by patient inspiration.</td>
</tr>
<tr>
<td>Bilevel-ST</td>
<td>Bilevel with a backup rate</td>
<td>Positive airway pressure that is higher during inspiration than expiration with a backup respiratory cycle length if the patient's breathing is slower than the preset rate.</td>
</tr>
<tr>
<td>VAPS</td>
<td>Volume-assured pressure support modes</td>
<td>Bilevel ST modes that use an algorithm to adjust inspiratory pressure support to meet a set tidal volume.</td>
</tr>
</tbody>
</table>
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

| iVAPS       | Intelligent volume-assured pressure support modes | Bilevel ST modes that use an algorithm to adjust inspiratory pressure support within a predetermined range to meet a set target ventilation. |

**Home Mechanical Ventilators**

In some patients, nocturnal respiratory assist devices are insufficient to address the respiratory failure. Non-invasive home mechanical ventilators (HMV) are proposed for the treatment of chronic respiratory failure that is refractory to a respiratory assist device. Mechanical ventilators are devices that deliver more controlled breathing with bilevel ventilation at a higher pressure. The ventilators may also have additional features compared to BiPAP machines such as alarms and battery backup power. Home mechanical ventilators can be used for patients with tracheostomy in the home, but may also be used with a non-invasive interface such as a mask or mouthpiece in patients who do not depend on 24 hour ventilation for survival. Current technology has decreased the size of home ventilators to around 10 pounds. In addition, some models may be wireless with battery backup, allowing greater mobility during the day.

**Titration**

Early studies with low intensity NPPV did not demonstrate health benefits in patients with hypercapnia. More recent studies have reinforced the importance of high-intensity NPPV (> 18 cm H2O) that is titrated to decrease hypercapnia. A high respiratory backup rate that is increased to the level of spontaneous breathing has also been shown to be important to achieve positive health outcomes. Manually set, laboratory or hospital titration of NPPV with pressure control and backup rate have been recommended for stable hypercapnic COPD. The goal of titration of inspiratory positive airway pressure is to achieve normocapnia, a reduction in transcutaneous CO2, or maximum tolerable inspiratory pressure. A fast rise in inspiratory pressure (rise time) allows enough time for expiration within the normal rate of breathing. In patients with air trapping and hyperinflation, use of positive end-expiratory pressure can also be beneficial.

A suggested protocol for in-laboratory titration of NPPV in patients with COPD in the U.S. is described by Orr et al (2020 Titration of NPPV is usually performed in a monitored environment after the patient has stabilized, as studies have not found an improvement in health outcomes when NPPV is started soon after an acute exacerbation. Polysomnography or respiratory monitoring may be used during titration to evaluate the presence of obstructive sleep apnea or hypoventilation. The
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy #  00829  
Original Effective Date:  04/01/2023  
Current Effective Date:  04/01/2023

inspiratory pressure is typically started at 6 to 8 cm H₂O of pressure support above the expiratory pressure and titrated to reduce hypercapnia. A Bilevel-ST (with backup rate) or a VAPS (volume assured) may be used if a Bilevel-S (without backup rate) fails to adequately reduce hypercapnia. Although titration in European studies has been performed with a hospital stay, this is not feasible in the U.S., and titration might be performed over several weeks in the patient's home by an external durable medical equipment (DME) provider.

Pulmonary Rehabilitation
Pulmonary rehabilitation is a personalized intervention that includes physical activity (eg, activities of daily living, endurance exercises and muscle strengthening), health education, and psychological support. It may be performed in the hospital, outpatient clinic, or home, and has been shown to reduce mortality, exacerbation rate, intensive care admissions, and emergency department visits. Pulmonary rehabilitation is common in Europe but is less frequently provided in the U.S.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Numerous CPAP and BiPAP devices are available in the U.S. Examples of HMV devices that have both invasive and non-invasive interfaces and are available in the U.S. are described in Table 2.

Table 2. Select Home Mechanical Ventilators with Non-invasive Interface

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>FDA clearance</th>
<th>Date</th>
<th>FDA product code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trilogy™ ‡ Evo Ventilator</td>
<td>Respironics</td>
<td>K181166</td>
<td>2019</td>
<td>NOU, CBK</td>
</tr>
<tr>
<td>Vivo 60</td>
<td>Breas</td>
<td>K160481</td>
<td>2016</td>
<td>NOU, CBK, DQA, CCK</td>
</tr>
<tr>
<td>Astral 100/150</td>
<td>ResMed</td>
<td>K152068</td>
<td>2016</td>
<td>NOU, CBK</td>
</tr>
<tr>
<td>Newport™ ‡</td>
<td>Medtronic</td>
<td>K121891</td>
<td>2012</td>
<td>NOU, CBK</td>
</tr>
</tbody>
</table>

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

<table>
<thead>
<tr>
<th>iVent</th>
<th>GE Healthcare</th>
<th>K092135</th>
<th>2009</th>
<th>NOU, CBK</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTV</td>
<td>Cardinal Health</td>
<td>K083688</td>
<td>2009</td>
<td>CBK</td>
</tr>
<tr>
<td>Puritan Bennet 540</td>
<td>Covidiien</td>
<td>K082966</td>
<td>2008</td>
<td>CBK</td>
</tr>
</tbody>
</table>

**Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Respiratory failure is characterized by low arterial blood oxygen (hypoxemia, PaO₂) and/or high arterial carbon dioxide (hypercapnia, PaCO₂ > 45 mmHg). Chronic respiratory insufficiency or failure can occur with chronic obstructive pulmonary disease (COPD) and may result in poor quality of life, sleepiness, hospital admission, intubation, and death. Non-invasive positive airway pressure ventilation (NPPV) including continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP) and home mechanical ventilators (HMV) that are pressure, rate and volume targeted are proposed for the treatment of COPD.

**Summary of Evidence**

For individuals who have COPD and OSA who receive CPAP, the evidence includes observational studies. Relevant outcomes are mortality, symptoms, morbid events, functional outcomes, quality of life, and hospitalization. Studies of patients with both COPD and OSA who do or do not use CPAP show a mortality benefit in patients with overlap syndrome who are treated with positive airway pressure. The greatest benefits occur in patients with COPD and hypercapnia and in older adults, and individuals with more comorbid conditions and higher complexity ratings. It should be noted that the threshold for what was considered hypercapnia was lower than in other studies on BiPAP that used a threshold of PaCO₂ > 52 mm Hg. Although the literature indicates that patients with COPD should be screened for OSA due to increased mortality in overlap syndrome, no studies were identified to indicate that CPAP would be prescribed in any manner other than would typically be recommended for patients with clinically significant OSA (see medical policy 00328). Patients with overlap syndrome can be treated with CPAP and, when CPAP is not tolerated, with BiPAP. The
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy #    00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have COPD and chronic respiratory failure who receive BiPAP, the evidence includes randomized controlled trials and systematic reviews of randomized controlled trials. Relevant outcomes are mortality, symptoms, morbid events, functional outcomes, quality of life, and hospitalization. The primary limitation of the evidence base is the heterogeneity of patient selection criteria and treatment parameters. The most recent trials indicate that bilevel NPPV improves hypercapnia in both patients with stable hypercapnia and in patients who have stabilized following an acute exacerbation. There is evidence that some health outcomes including function, readmissions, and death are improved; however, the strength of evidence is low. Several factors have been reported to be important to achieve benefit of NPPV. These are severe hypercapnia with PaCO$_2$ > 52 mmHg, use for at least 5 hours per night, and treatment with high intensity pressure. In addition, for patients with hypercapnia following an acute exacerbation, titration should occur at least 2 weeks after hospitalization when hypercapnia has stabilized. Under these conditions, the evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have COPD and chronic respiratory failure when BiPAP is inadequate who receive HMV, the evidence includes observational studies and an analysis of administrative claims data. Relevant outcomes are mortality, symptoms, morbid events, functional outcomes, quality of life, and hospitalization. There is low strength of evidence based on observational studies and claims data that NPPV reduces the number of hospital admissions or number of patients with hospitalization compared to either no device or BiPAP. Due to the severity of the condition, high quality prospective controlled trials are unlikely in patients who have failed BiPAP. HMV may be appropriate in situations where BiPAP is not adequate to obtain needed pressures or when daytime use and battery backup is needed. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

**Supplemental Information**

**Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given...
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Thoracic Society

Chronic Obstructive Pulmonary Disease
In 2020, the American Thoracic Society published an evidence-based clinical practice guideline on long-term non-invasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease (COPD). The society included the recommendations in Table 3, all of which were conditional due to moderate to very low certainty in the evidence base.

Table 3. American Thoracic Society Recommendations

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Strength of Recommendation</th>
<th>Level of Certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;We suggest the use of nocturnal noninvasive ventilation (NIV) in addition to usual care for patients with chronic stable hypercapnic COPD.&quot;</td>
<td>Conditional</td>
<td>Moderate</td>
</tr>
<tr>
<td>&quot;We suggest that patients with chronic stable hypercapnic COPD undergo screening for obstructive sleep apnea before initiation of long-term NIV.&quot;</td>
<td>Conditional</td>
<td>Very low</td>
</tr>
<tr>
<td>&quot;We suggest not initiating long-term NIV during an admission for acute on-chronic hypercapnic respiratory failure, favoring instead reassessment for NIV at 2–4 weeks after resolution.&quot;</td>
<td>Conditional</td>
<td>Low</td>
</tr>
<tr>
<td>&quot;We suggest not using an in-laboratory overnight polysomnogram (PSG) to titrate NIV in patients with chronic stable hypercapnic COPD who are initiating NIV.&quot;</td>
<td>Conditional</td>
<td>Very low</td>
</tr>
<tr>
<td>&quot;We suggest NIV with targeted normalization of PaCO₂ in patients with hypercapnic COPD on long-term NIV.&quot;</td>
<td>Conditional</td>
<td>Low</td>
</tr>
</tbody>
</table>

COPD: chronic obstructive pulmonary disease; NIV: non-invasive ventilation; PaCO₂: pressure of carbon dioxide; PSG: polysomnogram.
Hypercapnic COPD defined as PaCO₂ > 45 mmHg.
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

American College of Chest Physicians et al
In 2021, the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society published a technical expert panel report on optimal noninvasive ventilation for COPD. The panel recommends that overnight oxygen saturation should not be part of the criteria for bilevel positive airway pressure (BiPAP) and that home mechanical ventilators be considered when patients need any of the following:

- "Higher inspiratory pressures than those deliverable by E0471"
- FIO2 higher than 40% or 5 L/min nasally
- Ventilator support for 10 h per day or greater (ie, daytime use)
- Both sophisticated alarms and accompanying internal battery (high-dependency patient)
- Mouthpiece ventilation during the day
- Persistence of hypercapnia with PaCO2 ≥ 52 mm Hg despite adequate adherence to BiPAP therapy"

The panel strongly recommended the use of respiratory therapists in the home for initiation and ongoing support for positive pressure ventilation with either BiPAP or home ventilators.

National Institute for Health and Care Excellence Global
In 2019, the United Kingdom's National Institute for Health and Care Excellence (NICE) published a guideline for the diagnosis and management of COPD. NICE recommends that patients with COPD who have chronic hypercapnic respiratory failure despite adequate pharmacologic and oxygen therapy should be referred to a specialist center for consideration of long-term, non-invasive ventilation.

Global Initiative for Chronic Obstructive Pulmonary Disease
The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) published a revised report for 2022. GOLD recommendations include:

- "Pulmonary rehabilitation improves dyspnea, health status and exercise tolerance in stable patients (Evidence A)."
- "Pulmonary rehabilitation reduces hospitalization among patients who have had a recent exacerbation (≤ 4 weeks from prior hospitalization)(Evidence B)."
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

- "In patients with severe resting hypoxemia long-term oxygen therapy is indicated (Evidence A)."
- "In patients with stable COPD and moderate resting or exercise-induced arterial desaturation, prescription of long-term oxygen does not lengthen time to death or first hospitalization or provide sustained benefit in health status, lung function and 6-minute walk distance (Evidence A).
- "In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long term non-invasive ventilation may be considered (Evidence: B)."

Pronounced daytime persistent hypercapnia was reported as (PaCO$_2$ > 52 mmHg).

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
CMS mentions coverage of Ventilators in NCD Manual (Medicare National Coverage Determinations Manual (cms.gov). 2001 National Coverage Analysis Decision Memo (NCA - Noninvasive Positive Pressure RADs for COPD (CAG-00052N) - Decision Memo (cms.gov) states regarding Noninvasive Positive Pressure RADs for COPD that “Given the lack of data and clinical consensus, we will not make a national coverage decision at this time. Contractor discretion allows the contractors to make individual coverage determinations, including exceptions. We invite interested parties to share information with us and the carriers concerning appropriate study designs and outcome measures.”

In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Local Coverage Determination (LCD) is available for Respiratory Assist Devices (LCD - Respiratory Assist Devices (L33800) (cms.gov), stating that “The intent of the LCD is to enforce the requirement that only select individuals use ventilators when appropriate. The ventilator-related disease groups noted in the NCD overlap conditions described in the respiratory assist devices (RAD) LCD, which is used to determine coverage for bi-level PAP devices.”

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

The Centers for Medicare and Medicaid Services has requested topic review by the Agency for Healthcare Research and Quality (AHRQ). The technology assessment was published February 2020.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 4.

Table 4. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01037387</td>
<td>Effect of the Noninvasive Mechanical Ventilation on the Daily Physical Activity and the Inflammatory Biomarkers in Stable Patients With COPD</td>
<td>50</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>NCT02811588</td>
<td>Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation Amendment: Home Tele-Monitoring of Non-Invasive Ventilation in Chronic Obstructive Pulmonary Disease</td>
<td>550</td>
<td>Jun 2023</td>
</tr>
<tr>
<td>NCT03647462</td>
<td>The Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized Chronic Obstructive Pulmonary Disease Patients: the COPD Readmit Clinical Trial</td>
<td>100</td>
<td>Apr 2025</td>
</tr>
<tr>
<td>NCT03221101</td>
<td>Home Non Invasive Ventilation Versus Long Term Oxygen Therapy Alone in COPD Survivors After Acute Hypercapnic Respiratory Failure. A</td>
<td>86</td>
<td>Dec 2025</td>
</tr>
</tbody>
</table>
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>French Multicenter Randomized Controlled Trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unpublished</td>
<td>Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a</td>
<td>150</td>
<td>July 2020 (unknown)</td>
</tr>
<tr>
<td></td>
<td>NIV-treated Exacerbation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01513655a</td>
<td>Optimal Positive Airway Pressure in Overlap Syndrome: a Randomized</td>
<td>70</td>
<td>Sep 2020 (unknown)</td>
</tr>
<tr>
<td></td>
<td>Controlled Trial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
a Denotes industry-sponsored or cosponsored trial.

References

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy #  00829  
Original Effective Date:  04/01/2023  
Current Effective Date:  04/01/2023  


Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023


https://www.nice.org.uk/guidance/ng115.


22. Local Coverage Determination (LCD) Respiratory Assist Devices (L33800) (cms.gov).

Policy History
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023
01/05/2023 Medical Policy Committee review
01/11/2023 Medical Policy Implementation Committee approval. New policy.
Next Scheduled Review Date: 01/2024

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>No codes</td>
</tr>
<tr>
<td>HCPCS</td>
<td>E0466, E0470, E0471</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>J44.0-J44.9, J96.10-J96.12, J96.20-J96.22, J96.90-J96.92</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.
Non-Invasive Positive Airway Pressure (Including Non-Invasive Home Mechanical Ventilation)

Policy # 00829
Original Effective Date: 04/01/2023
Current Effective Date: 04/01/2023

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.